Vanguard Fiduciary Trust
ADPT icon

Vanguard Fiduciary Trust’s Adaptive Biotechnologies ADPT Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20M Buy
934,709
+63,750
+7% +$977K ﹤0.01% 1421
2026
Q1 		$12.1M Buy
+870,959
New +$13.9M ﹤0.01% 1609

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Fiduciary Trust's ADPT Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Adaptive Biotechnologies (ADPT) stake by 7.3% in Q2 2026, buying an estimated $977K and bringing the position to 934,709 shares worth $20M. The position accounts for ﹤0.01% of the portfolio, ranked #1421.

Vanguard Fiduciary Trust first reported a position in ADPT in Q1 2026 and has held it in 2 quarters since. 299 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Vanguard Fiduciary Trust held 934,709 shares of Adaptive Biotechnologies worth $20M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 63,750 Adaptive Biotechnologies shares in Q2 2026, an estimated $977K.
  • Adaptive Biotechnologies made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1421 holding.
  • Vanguard Fiduciary Trust first reported a position in Adaptive Biotechnologies in Q1 2026 and has held it in 2 quarters since.
  • 299 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.